Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.60 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10476067 | 0.98 | ACHE (0.62) | ACHEEPHX2PLA2G2A | |
| SCHEMBL7168074 | 0.93 | ACHE (0.71) | ACHEEPHX2PLA2G2A | |
| SCHEMBL7168064 | 0.93 | ACHE (0.71) | ACHEEPHX2PLA2G2A | |
| SCHEMBL480293 | 0.91 | ACHE (0.68) | ACHEEPHX2 | |
| SCHEMBL3655324 | 0.89 | EPHX2 (0.74) | ACHEEPHX2PLA2G2A | |
| SCHEMBL19400387 | 0.88 | EPHX2 (0.76) | ACHEEPHX2PLA2G2A | |
| SCHEMBL19400363 | 0.88 | EPHX2 (0.76) | ACHEEPHX2PLA2G2A | |
| SCHEMBL19400357 | 0.88 | EPHX2 (0.76) | ACHEEPHX2PLA2G2A | |
| SCHEMBL3629434 | 0.88 | EPHX2 (0.76) | ACHEEPHX2PLA2G2A | |
| SCHEMBL19400416 | 0.88 | EPHX2 (0.76) | ACHEEPHX2PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791129-B2 | Phenylquinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | claimed |
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-11 | — | — | US | claimed |
| EP-1307226-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Bristol-Myers Squibb Pharma Company (US) | 2003-05-07 | — | — | EP | claimed |
| WO-2001097848-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | claimed |
| EP-0944619-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 1999-09-29 | — | — | EP | claimed |
| WO-1998023608-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-06-04 | — | — | WO | claimed |
| EP-0828737-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-18 | — | — | EP | claimed |
| WO-1996037492-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | claimed |
| WO-2024043313-A1 | REVERSIBLE THERMOCHROMIC COMPOSITION, MICROENCAPSULATED PIGMENT USING SAID REVERSIBLE THERMOCHROMIC COMPOSITION, WRITING TOOL, AND TOY | 三菱ケミカル株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2021-03-04 | — | — | US | disclosed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | disclosed |
| WO-2019147182-A1 | ANTIATHEROSCLEROTIC AGENTS | MEDSCIENTA AB (SE) | 2019-08-01 | — | — | WO | disclosed |
| US-RE47221-E1 | Tricyclic compounds | ABBVIE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-01-08 | — | — | US | disclosed |
| EP-0741715-A1 | NOVEL HUMAN LEUKOCYTE ELASTASE (HLE) INHIBITORS, AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | SRI INTERNATIONAL (US) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995020581-A1 | NOVEL HUMAN LEUKOCYTE ELASTASE (HLE) INHIBITORS, AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | SRI INTERNATIONAL (US) | 1995-08-03 | — | — | WO | disclosed |
| EP-0629196-A1 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK SHARP & DOHME LTD. (GB) | 1994-12-21 | — | — | EP | disclosed |
| WO-1994001402-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS TACHYKININ DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1994-01-20 | — | — | WO | disclosed |
| US-5270334-A | 4-methoxy-5-methyl-pyran-3-ol natural products and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1993-12-14 | — | — | US | disclosed |
| WO-1993018023-A1 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK SHARP & DOHME LIMITED (GB) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | HSP90B1, HSP90AB1, HSP90AA1 | ACHE 4751/4885EPHX2 4515/4885PLA2G2A 4265/4885 |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | ACHE 3126/4885EPHX2 885/4885PLA2G2A 4317/4885 |
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | SERPINB1, ELANE, EPX | ACHE 2375/4885EPHX2 637/4885PLA2G2A 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.